Form 4: Progyny Executive Michael Sturmer Reports Stock Transactions

Progyny's President, Michael Sturmer, reports acquisition of stock options and restricted stock units, as well as the sale of common stock under a pre-arranged trading plan.

Summary

• Michael Sturmer, President of Progyny, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On March 4, 2024, Sturmer acquired 250,000 shares of common stock underlying restricted stock units (RSUs) and was granted options to purchase 600,000 shares.
• These grants were annual merit grants made pursuant to the Issuer's 2019 Equity Incentive Plan.
• 25% of the RSUs and options will vest on March 4, 2025, with the remainder vesting in equal quarterly installments through March 4, 2028, contingent upon continued service.
• On April 1, 2024, Sturmer sold 4,515 shares and 1,880 shares of common stock at a price of $37.6 per share under a Rule 10b5-1 trading plan established on August 31, 2023.
• Following these transactions, Sturmer directly owns 384,553 shares of common stock and holds options for 600,000 shares.

Sentiment

Score: 6

Explanation: The document is neutral in sentiment. It simply reports transactions by an executive. The grants are positive, but the sales are neutral due to the 10b5-1 plan.

Positives

• The grant of RSUs and stock options to the President aligns his interests with the long-term performance of the company.
• The vesting schedule of the RSUs and options incentivizes continued service and commitment to Progyny.

Negatives

• The sale of shares by the President, even under a pre-arranged trading plan, could be perceived negatively by some investors.

Risks

• Future stock price fluctuations could impact the value of the RSUs and stock options.
• Changes in employment status could affect the vesting of the RSUs and stock options.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options extends to March 4, 2028, suggesting a long-term commitment from the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Stock option and RSU grants are common compensation practices in the technology and healthcare industries, used to attract and retain executive talent.
• Vesting schedules are typically structured to align with industry norms, often spanning three to five years with quarterly or annual vesting intervals.
• Rule 10b5-1 trading plans are frequently used by executives to diversify their holdings while avoiding accusations of insider trading, similar to practices at companies like Teladoc and UnitedHealth Group.

Stakeholder Impact

• Shareholders may monitor these transactions for insights into executive sentiment.
• Employees may view the equity grants as a positive sign of company commitment to its leadership.

Key Dates